News

7th January 2025

BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial

26th November 2024

BerGenBio to Present Company Update at DNB Nordic Healthcare Conference

20th November 2024

BerGenBio Appoints Olav Hellebø as CEO

13th November 2024

BerGenBio Third Quarter Results 2024

6th November 2024

BerGenBio ASA: Invitation to third quarter 2024 results webcast

10th October 2024

CEO Martin Olin steps down

10th October 2024

BerGenBio ASA: Minutes from Extraordinary General Meeting

7th October 2024

BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients

19th September 2024

BERGENBIO ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING